Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SILO PharmaSILO 42 EV-to-EBIT is 0.40 as of Sep. 11, 2026. GuruFocus rates SILO with a GF Score™ of 42/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 368 Biotechnology companies, SILO Pharma ranks better than 86.96% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
SILO Pharma's Enterprise Value for the quarter that ended in Jun. 2026 was $1.58 Mil.
SILO Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO Pharma EV-to-EBIT Related Terms
SILO Pharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for SILO Pharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SILO Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SILO Pharma EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SILO Pharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where SILO Pharma's EV-to-EBIT falls into.
SILO Pharma's current Enterprise Value is $-1.75 Mil.
SILO Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO Pharma (SILO) has a EV-to-EBIT of 0.40 as of Sep. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SILO Pharma and its competitors. According to the industry distribution chart, SILO Pharma ranks #48 out of 368 companies in the Biotechnology industry, placing it in the top 13%.
Is SILO Pharma's EV-to-EBIT too high?
SILO Pharma's current EV-to-EBIT is 0.40. The Biotechnology industry median EV-to-EBIT is 15.50. SILO Pharma's value of 0.40 is 97.4% below this industry median. Based on the distribution chart, SILO Pharma ranks #48 out of 368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SILO Pharma has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's EV-to-EBIT compare to ELAB and GLMD?
According to the Biotechnology industry distribution chart, SILO Pharma ranks #48 out of 368 companies for EV-to-EBIT. This places SILO Pharma in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.50. SILO Pharma's value of 0.40 is 97.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.50, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SILO Pharma's current EV-to-EBIT of 0.40 is 97.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SILO Pharma and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SILO Pharma's current EV-to-EBIT is 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.10 — trading 39% below its estimated fair value. The current EV-to-EBIT is 0.40 and 97.4% below the Biotechnology industry median of 15.50. SILO Pharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For SILO Pharma (SILO), the current EV-to-EBIT is 0.40 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SILO Pharma (SILO) Overvalued in 2026?
Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued.
The current stock price of $2.10 is trading 39% below its estimated GF Value™ of $3.44.
GuruFocus considers SILO Pharma to be Possible Value Trap.
Key valuation signals for SILO:
EV-to-EBIT: 0.40
GF Value™: $3.44 vs. price of $2.10 (39% below fair value)
Industry Position: 97.4% below the Biotechnology median (#48 of 368)
No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
42GF Score
Get the complete analysis for SILO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SILO has been successfully added to your 
